Get Rid of Those Silos: Linda Sullivan, Artem Andrianov, and Johann Proeve on How To Optimize Clinical Trials through RBQM
Linda chats about Risk-Based Quality Management (RBQM) with Artem Andrianov, CEO of Cyntegrity and Johanna Proeve, Chief Scientific Officer at Cyntegrity. Artem says his vision is to create the “Bloomberg for Pharma,” a platform that shares RBQM risk mitigation strategy information across the industry. Artem adds that Cyntegrity’s technology platform allows organizations to manage the entire quality management cycle, rather than continuing with a traditional “siloed” approach. This holistic approach, he explains, enables pharmaceutical companies to become more efficient in reducing risk. Johann discusses how organizations are recognizing that, especially during this pandemic, Excel doesn’t always work for managing RBQM, especially in larger clinical trials, and that companies — both CROs and sponsors — are implementing RBQM technology and asking for additional training. Additionally, the onslaught of COVID has led to data quality deterioration — a development that Cyntegrity, with its robust platform — has been able to help customers assess and monitor. And in the TRIO segment, you’ll want to hear Artem’s and Johann’s answers to these questions: What is the biggest challenge facing the clinical trials industry? What’s the best new innovation? What‘s your top optimization takeaway?